ABBV-969 / AbbVie - LARVOL DELTA

First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) (ESMO 2024) - P1 | "Pts will be enrolled in US, Israel, Japan, and Australia in part 1; additional locations may be added. Table: 1660TiP"

Clinical • Metastases • P1 data • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor • STEAP1

A Study to Assess Adverse Events, and How Intravenously (IV) Infused ABBV-969 Moves Through the Bodies of Adult Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov) - P1 | N=120 | Recruiting | Sponsor: AbbVie

Adverse events • Metastases • New P1 trial • Genito-urinary Cancer • Metastatic Castration-Resistant Prostate Cancer • Oncology • Prostate Cancer • Solid Tumor